N-[1-(4-acetylaminobenzyl)-1H-pyrazol-3-yl]-2-(4-dimethylaminophenyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[1-(4-acetylaminobenzyl)-1H-pyrazol-3-yl]-2-(4-dimethylaminophenyl)acetamide
• 英文别名: N-[1-[(4-acetamidophenyl)methyl]pyrazol-3-yl]-2-[4-(dimethylamino)phenyl]acetamide
• 化学式: C₂₂H₂₅N₅O₂
• 分子量: 391.473
• InChiKey: AMXSWGRIUVSMFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-乙酰胺基苄基氯 在 四丁基溴化铵 、 铁粉 、 potassium carbonate 、 氯化铵 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 丙酮 为溶剂， 反应 50.0h， 生成 N-[1-(4-acetylaminobenzyl)-1H-pyrazol-3-yl]-2-(4-dimethylaminophenyl)acetamide
  参考文献：
  名称：

  Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

  摘要：

  We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

  DOI：

  10.1021/acs.jmedchem.7b01236

文献信息

• Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies
  作者：Olivier Bezençon、Bibia Heidmann、Romain Siegrist、Simon Stamm、Sylvia Richard、Davide Pozzi、Olivier Corminboeuf、Catherine Roch、Melanie Kessler、Eric A. Ertel、Isabelle Reymond、Thomas Pfeifer、Ruben de Kanter、Michael Toeroek-Schafroth、Luca G. Moccia、Jacques Mawet、Richard Moon、Markus Rey、Bruno Capeleto、Elvire Fournier

  DOI：10.1021/acs.jmedchem.7b01236

  日期：2017.12.14

  We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.